[1] Shi L, Wang Y, Cao X, et al. Increasing positive rate of IgG against hepatitis E virus with steady IgM positivity and clinical incidence: A retrospective seroprevalence time series analysis of HEV from 2012 to 2021 in Chongqing, China. J Med Virol, 2023, 95:e28872.
[2] Baymakova M, Kunchev M, Mihaylova-Garnizova R, et al. Comparative Analysis on Clinical Characteristics Among Patients with Acute Hepatitis A Virus (HAV) and Patients with Acute Hepatitis E Virus (HEV): A Single-Center Retrospective Study from Bulgaria. Infect Drug Resist, 2023, 16:3349-3366.
[3] Kogias D, Skeva A, Smyrlis A, et al. Hepatitis E Virus (HEV) Infection in Hemodialysis Patients: A Multicenter Epidemiological Cohort Study in North-Eastern Greece. Pathogens, 2023, 12.
[4] Schofield D, Purcell R, Nguyen H, et al. Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine. Vaccine 2003;22:257-67.
[5] Purcell R, Emerson S. Hepatitis E: an emerging awareness of an old disease. Journal of hepatology, 2008, 48:494-503.
[6] Kaić B, Vilibić Cavlek T, Filipović S, et al. [Epidemiology of viral hepatitis]. Acta Med Croatica, 2013, 67(4):273-279.
[7] Abe K, Li T, Ding X, et al. International collaborative survey on epidemiology of hepatitis E virus in 11 countries. Southeast Asian J Trop Med Public Health, 2006, 37:90-95.
[8] Dalton H, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries. The Lancet Infectious diseases, 2008, 8:698-709.
[9] Meng X. Recent advances in Hepatitis E virus. J Viral Hepat, 2010, 17:153-161.
[10] Colson P, Borentain P, Queyriaux B, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis, 2010, 202:825-834.
[11] Kamar N, Izopet J, Rostaing L. Hepatitis E virus infection. Curr Opin Gastroenterol, 2013, 29:271-278.
[12] Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation, 2010, 89:353-360.
[13] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol, 2018, 68:1256-1271.
[14] Marion O, Lhomme S, Del Bello A, et al. Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. J Hepatology, 2019, 70:206-209.
[15] Montpellier C, Wychowski C, Sayed I, et al. Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. Gastroenterology, 2018, 154:211-223.e8.
[16] Yin X, Ying D, Lhomme S, et al. Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection. Proc Natl Acad Sci U S A, 2018, 115:4773-4778.
[17] Ying D, He Q, Tian W, et al. Urine is a viral antigen reservoir in hepatitis E virus infection. Hepatology, 2023, 77:1722-1734.
[18] Marion O, Capelli N, Lhomme S, et al. Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. J Infec, 2019, 78:232-240.
[19] Geng Y, Zhao C, Huang W, et al. Detection and assessment of infectivity of hepatitis E virus in urine. J Hepatol, 2016, 64:37-43.
[20] Behrendt P, Bremer B, Todt D, et al. Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. Liver int, 2021, 41:1815-1823. |
